Stock Scorecard
Stock Summary for Verona Pharma Plc (VRNA) - $106.94 as of 10/8/2025 8:10:43 AM EST
Total Score
7 out of 30
Safety Score
41 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for VRNA
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for VRNA
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for VRNA
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for VRNA
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for VRNA (41 out of 100)
| Stock Price Rating (Max of 10) | 10 |
| Historical Stock Price Rating (Max of 10) | 4 |
| Stock Price Trend (Max of 10) | 10 |
| Book Value (Max of 10) | 3 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 2 |
| Analyst Strong Buy Ratings (Max of 5) | 0 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 3 |
| Trading Volume (Max of 10) | 9 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for VRNA
Financial Details for VRNA
Company Overview |
|
|---|---|
| Ticker | VRNA |
| Company Name | Verona Pharma Plc |
| Country | USA |
| Description | Verona Pharma PLC is a clinical-stage biopharmaceutical company based in London, specializing in the development and commercialization of innovative therapies for respiratory diseases characterized by significant unmet medical needs. Its lead candidate, ensifentrine, is a dual inhibitor of the enzymes dipeptidyl peptidase I and neutrophil elastase, aimed at improving lung function in patients with chronic obstructive pulmonary disease (COPD) and asthma. By focusing on advancing its robust pipeline, Verona Pharma is positioned to make a meaningful impact in the respiratory therapeutic area, appealing to institutional investors seeking opportunities in the biopharmaceutical sector. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 6/30/2025 |
| Next Earnings Date | 11/11/2025 |
Stock Price History |
|
| Last Day Price | 106.94 |
| Price 4 Years Ago | 6.72 |
| Last Day Price Updated | 10/8/2025 8:10:43 AM EST |
| Last Day Volume | 1,871,959 |
| Average Daily Volume | 1,466,766 |
| 52-Week High | 106.93 |
| 52-Week Low | 31.09 |
| Last Price to 52 Week Low | 243.97% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 22.22 |
| Sector PE | 41.70 |
| 5-Year Average PE | -873.36 |
| Free Cash Flow Ratio | 20.77 |
| Industry Free Cash Flow Ratio | 14.45 |
| Sector Free Cash Flow Ratio | 30.25 |
| Current Ratio Most Recent Quarter | 10.71 |
| Total Cash Per Share | 5.15 |
| Book Value Per Share Most Recent Quarter | 3.24 |
| Price to Book Ratio | 33.01 |
| Industry Price to Book Ratio | 29.58 |
| Sector Price to Book Ratio | 32.02 |
| Price to Sales Ratio Twelve Trailing Months | 40.98 |
| Industry Price to Sales Ratio Twelve Trailing Months | 44.16 |
| Sector Price to Sales Ratio Twelve Trailing Months | 20.22 |
| Analyst Buy Ratings | 1 |
| Analyst Strong Buy Ratings | 0 |
Share Statistics |
|
| Total Shares Outstanding | 84,979,000 |
| Market Capitalization | 9,087,654,260 |
| Institutional Ownership | 92.22% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | -218.96% |
| Reported EPS 12 Trailing Months | -1.04 |
| Reported EPS Past Year | -0.03 |
| Reported EPS Prior Year | -1.81 |
| Net Income Twelve Trailing Months | -81,187,000 |
| Net Income Past Year | -173,418,000 |
| Net Income Prior Year | -54,369,000 |
| Quarterly Revenue Growth YOY | 0.00% |
| 5-Year Revenue Growth | 609.54% |
| Operating Margin Twelve Trailing Months | 12.90% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 438,016,000 |
| Total Cash Past Year | 399,757,000 |
| Total Cash Prior Year | 271,772,000 |
| Net Cash Position Most Recent Quarter | 195,582,000 |
| Net Cash Position Past Year | 279,416,000 |
| Long Term Debt Past Year | 120,341,000 |
| Long Term Debt Prior Year | 48,374,000 |
| Total Debt Most Recent Quarter | 242,434,000 |
| Equity to Debt Ratio Past Year | 0.63 |
| Equity to Debt Ratio Most Recent Quarter | 0.53 |
| Total Stockholder Equity Past Year | 204,559,000 |
| Total Stockholder Equity Prior Year | 249,283,000 |
| Total Stockholder Equity Most Recent Quarter | 278,273,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -73,606,013 |
| Free Cash Flow Per Share Twelve Trailing Months | -0.87 |
| Free Cash Flow Past Year | -122,783,000 |
| Free Cash Flow Prior Year | -50,222,004 |
Options |
|
| Put/Call Ratio | 0.00 |
| Has Options | False |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.00 |
| MACD Signal | 0.00 |
| 20-Day Bollinger Lower Band | 0.00 |
| 20-Day Bollinger Middle Band | 0.00 |
| 20-Day Bollinger Upper Band | 0.00 |
| Beta | 0.05 |
| RSI | 0.00 |
| 50-Day SMA | 0.00 |
| 150-Day SMA | 0.00 |
| 200-Day SMA | 0.00 |
System |
|
| Modified | 10/7/2025 12:16:17 PM EST |